Author

John C Byrd

Distinguished University Professor, The Ohio State University - Cited by 1,02,441 - Hematology - Drug Development

Biography

Dr John C Byrd physician scientist who has done translational and clinical drug development for two decades. My laboratory and clinical work has directly resulted in 4 drugs getting FDA approval. This experience bridges close interaction with industry as a consultant to develop and implement a successful development plan (Calistoga, Idelalisib) to performing pre-clinical and clinical work in my University role focused on a single class of drugs that transformed the care of CLL (Ibrutinib, Acalabrutinib) and other B-cell malignancies.
Title
Cited by
Year
Ventricular arrhythmias and sudden death events following acalabrutinib initiation
SA Bhat, J Gambril, L Azali, ST Chen, L Rosen, M Palettas, TE Wiczer, ...Blood, The Journal of the American Society of Hematology 140 (20), 2142-2145, 2022202
16
2022
An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia
A Lasry, B Nadorp, M Fornerod, D Nicolet, H Wu, CJ Walker, Z Sun, ...Nature Cancer 4 (1), 27-42, 2023202
13
2023
Dysregulation of prmt5 in chronic lymphocytic leukemia promotes progression with high risk of richter’s transformation
ZA Hing, JS Walker, EC Whipp, L Brinton, M Cannon, P Zhang, S Sher, ...Nature Communications 14 (1), 97, 2023202
6
2023
Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated bruton tyrosine kinase inhibitor for B-Cell malignancies: updated analysis of the open-label phase 1/2 dose …
JA Woyach, IW Flinn, FT Awan, H Eradat, D Brander, M Tees, SA Parikh, ...Blood 140 (Supplement 1), 7004-700, 2022202
6
2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
S Sher, E Whipp, J Walker, P Zhang, L Beaver, K Williams, S Orwick, ...Leukemia 37 (2), 326-338, 2023202
4
2023
Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with> 4 Years of Follow-up
Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with> Years of Follow-upRR Furman, WG Wierda, A Schuh, PEM Patten, JM Chaves, JR Brown, ...Blood 10 (Supplement 1), 9873-9875, 2022202
4
2022
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
K Mrózek, J Kohlschmidt, JS Blachly, D Nicolet, AJ Carroll, KJ Archer, ...Leukemia 7 (4), 788-798, 20220
3
2023
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential
M Yano, JC Byrd, N MuthusamyCancers 14 (2), 5787, 2022202
3
2022
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase study with laboratory correlatesAN Saliba, SH Kaufmann, EM Stein, PA Patel, MR Baer, W Stock, ...Blood Advances 7 (11), 360-363, 030
2
2023
Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation
RJ Tokarski II, CM Sharpe, AC Huntsman, BK Mize, OR Ayinde, EH Stahl, ...European Journal of Medicinal Chemistry 254, 5342, 2023202
1
2023
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-9 (Alliance).JA Woyach, J Yin, JR Brown, S Dinner, G Lozanski, RF Little, C Miller, ...Journal of Clinical Oncology 4 (6_suppl), 7500-7500, 2023202
1
2023
Cardiovascular magnetic resonance imaging in patients with ibrutinib-associated cardiotoxicity
B Buck, AP Chum, M Patel, R Carter, H Nawaz, V Yildiz, P Ruz, T Wiczer, ...JAMA oncology 9 (4), 552-555, 2023202
1
2023
Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies
S Elgamal, T Clevenger, M Gulrajani, J Cheung, EG Jeremy, S Fobare, ...Blood 40 (Supplement ), 5936-5938, 2022202
1
2022
Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM1-mutated and FLT3-ITD wild-type acute myeloid …
Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM-mutated and FLT3-ITD wild-type acute myeloid …U Borate, R Li, Y Huang, RT Swords, E Traer, E Stein, JM Foran, MR Baer, ...Blood 40 (Supplement ), 6200-6203, 2022202
1
2022

Referred From: https://scholar.google.com/citations?user=awFewVkAAAAJ&hl=en

Cited by
Citations 102441
h-index 144
i10-index 778
Recommended Journals
Open Access Journals